New Blood Tests Show Promise in Early Alzheimer’s Detection

Research is advancing rapidly in the field of Alzheimer’s disease detection, particularly through the development of blood tests that could serve as early warning systems. Recent studies indicate that tracking changes in specific protein biomarkers over time may provide more reliable insights than relying on a single test result. Notably, a study presented in March 2023 reveals that obesity can dilute Alzheimer’s-related proteins, complicating the accuracy of blood tests.

This study highlights a significant finding: individuals concerned about their memory who showed normal performance on cognitive tests often exhibited a marked increase in Alzheimer’s-linked proteins in their blood over five years, especially those with early indicators in their spinal fluid. As a result, some participants eventually developed abnormal markers associated with the disease, despite initial normal tests.

Advancements in Detection Technology

Historically, diagnosing Alzheimer’s has depended on brain scans or spinal taps. Typically, a positron emission tomography (PET) scan involves injecting a radioactive tracer to highlight amyloid protein clusters in the brain, which are associated with cognitive decline. When amyloid levels become elevated, they can trigger changes in another protein, tau, which disrupts neuronal communication and leads to memory loss. Spinal taps can measure these proteins in the cerebrospinal fluid. Unfortunately, many patients only receive these assessments during the later stages of cognitive decline, as they can be expensive and difficult to access due to limited resources and insurance barriers.

Given the rising number of Alzheimer’s diagnoses, there is an urgent need for more accessible diagnostic methods. In the past three to five years, blood biomarker testing has gained significant traction. Recently, the FDA approved two blood tests that identify Alzheimer’s-related biomarkers, and the Alzheimer’s Association has issued clinical guidelines for their use in specialized care settings.

According to Sheena Aurora, a practicing neurologist and vice president of medical affairs at the Alzheimer’s Association, each test serves distinct purposes. One acts as a “rule-out” test, helping primary care providers determine if amyloid accumulation is likely responsible for a patient’s symptoms. The second is a “rule-in” test for specialists, indicating a higher probability of Alzheimer’s-related proteins in the brain.

Aurora emphasizes that these tests are only one part of a comprehensive diagnostic process. They should be used alongside family history, cognitive assessments, and imaging, rather than as standalone indicators. “They’re not for risk. They are for patients who have objective signs of mild cognitive impairment,” she noted.

Challenges and Limitations

Despite the potential benefits of blood tests, caution is warranted. Chronic conditions, such as kidney disease, can compromise the reliability of results. Research by Corey Bolton, a clinical neuropsychologist at Vanderbilt University Medical Center, reveals that kidney function can affect biomarker levels, rendering results unreliable for approximately one-third of older adults with kidney issues. The study identified that mild kidney dysfunction could significantly alter levels of key biomarkers, including the neurofilament light chain, which indicates nerve damage.

Given that approximately 34% of Americans aged 65 and older have chronic kidney disease, understanding how this condition impacts Alzheimer’s testing is crucial. Bolton noted that while researchers are exploring workarounds, such as protein ratios, these solutions still require validation across diverse populations.

The complexity of blood tests is compounded by the need to account for factors like obesity and vascular conditions, which can alter protein levels. For instance, a study involving 407 participants demonstrated that initial results indicated a lower likelihood of Alzheimer’s signals among individuals with a higher body mass index. However, over time, those participants exhibited significant increases in biomarkers linked to Alzheimer’s compared to their non-obese counterparts.

The findings underline the importance of longitudinal testing, as a single test offers only a snapshot of a person’s cognitive health. Continuous monitoring can provide a clearer understanding of how Alzheimer’s disease may develop over time.

Research conducted by Argonde C. van Harten at the Alzheimer Center Amsterdam followed 298 individuals who reported memory concerns yet performed well on cognitive tests. Over five years, the study measured Alzheimer’s-related proteins and found that a rapid increase in these proteins correlated with declines in cognitive function. Approximately 20% of participants who initially presented with normal biomarker levels later displayed abnormal results.

Van Harten acknowledged that the group studied was relatively young, with few chronic conditions, which may limit the applicability of the findings. Nonetheless, as researchers strive to enhance the accuracy of Alzheimer’s diagnostics, the potential of blood-based biomarkers offers a minimally invasive approach to understanding underlying biological changes.

In conclusion, while blood tests for Alzheimer’s detection show great promise, their application must be approached with caution. Ongoing research is essential to refine these tools and ensure they can accurately predict the disease’s progression in diverse populations. As the field continues to evolve, the hope remains that early identification of Alzheimer’s will lead to timely interventions and improved patient outcomes.